The role of BARD1 Cys557Ser varient or BARD1 haplotypes as modifiers of BRCA1/2 associated breast cancer risk was further evaluated in a cohort of 5546 BRCA1 and 2865 BRCA2 mutation carriers. Here, BRCA2 is linked to breast carcinoma.